Elucidation of Cancer Killing Mechanisms in New Cancer Therapy Techniques Using Synchrotron Radiation

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K14502
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 28030:Nanomaterials-related
• Research Institution: National Institutes for Quantum Science and Technology
• Principal Investigator: Shiro Ayumi (瀬ノ内鮎美) 国立研究開発法人量子科学技術研究開発機構, 関西光科学研究所 放射光科学研究センター, 主任研究員 (60707446)
• Project Period (FY): 2021-04-01 – 2023-03-31
• Keywords: 放射光単色Ⅹ線 / 増感剤 / ナノ粒子 / 腫瘍スフェロイド

Outline of Final Research Achievements

Drugs that increase the killing effect of radiotherapy for cancer are called sensitizers, and have been studied to improve the efficiency of radiotherapy. The sensitizers developed by Tamanoi et al. have a sensitizing effect that is at one order of magnitude higher than that of conventional sensitizers. To elucidate the mechanism, this study quantified the irradiation X-ray dose and examined the electron spectrum and photon flux by simulation. The absorbed dose was estimated to be 0.03 Gy/sec from the photon flux. In addition, it was confirmed by simulation that there were differences in electron spectra and photon fluxes depending on the presence or absence of iodine.

Free Research Field

放射線生物学

Academic Significance and Societal Importance of the Research Achievements

本研究のがん殺傷技術は単色X線を利用することから正常細胞への影響が少ないため、副作用が少なく患者への負担が小さいがん治療方法の確立につながるものである。今後さらに正確な吸収線量の決定を進めることで、得られた知見が新たな低侵襲性の治療方法への開発に資すると期待される。